Altre lingue Bausch + Lomb Corporation Toronto S.E.

Azioni

BLCO

CA0717051076

Mercato chiuso - Toronto S.E. Altri mercati azionari 21:20:16 24/05/2024			Variaz. 5gg	Var. 1 gen.
20,61 ^CAD	+1,63%		+3,46%	-9,09%

06/05	Le azioni di Bausch + Lomb salgono dopo l'upgrade di Morgan Stanley	MT
06/05	BAUSCH + LOMB CORPORATION : via al Buy per Morgan Stanley	ZM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Bausch Health Companies - Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024	20/05
Bausch Health Announces 2024 Annual Meeting of Shareholder Results	16/05
Bausch + Lomb : 2023 Report	16/05
Bausch + Lomb Shares Rise After Morgan Stanley Upgrade	06/05
Bausch Health Announces First Quarter 2024 Results	03/05
RBC Capital Reviews Bausch + Lomb's Q1 Results	02/05
Needham Says Bausch + Lomb's Q1 Showed a "Strong Start" to The Year	01/05
Bausch + Lomb Q1 Loss Widens, Revenue Increases	01/05
Bausch + Lomb Q1 Net Loss Widens, But Revenue Higher; Raises 2024 Revenue Growth Guidance	01/05
Bausch + Lomb: Q1 Earnings Snapshot	01/05
Bausch + Lomb Brief: Raising Full-Year 2024 Constant Currency Revenue Growth Guidance	01/05
Bausch + Lomb Brief: Q1 Adjusted EBITDA (non-GAAP) of US$180 Million	01/05
Bausch + Lomb Brief: Q1 Revenue of US$1.099 Billion; GAAP Net Loss Attributable of $167 Million	01/05
Bausch + Lomb Announces First-Quarter 2024 Results	01/05
Bausch + Lomb Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	01/05
Bausch + Lomb Announces Presentation of New Data at the Association for Research in Vision and Ophthalmology Annual Meeting	29/04
Bausch + Lomb Says Study Shows Improvements in Dry Eyes With Nutritional Supplement	25/04
Bausch + Lomb Reports "Statistically Significant" Results From Study of Nutritional Supplement for Dry Eyes	25/04
Bausch + Lomb Brief: Announcing "Statistically Significant" Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes	25/04
Bausch + Lomb Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes	25/04

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Bausch + Lomb Corporation Toronto S.E.

Azioni

BLCO

CA0717051076

Altre lingue

Filtri